Publications

  • Davis AK, McMyn NF, Lau M, Morishima Y, Osawa Y. Hsp70:CHIP ubiquitinates dysfunctional but not native neuronal NO synthase. Molecular Pharmacology. (2020) PMID 32591478 DOI: 10.1124/mol.120.119990

  • Davis AK, Pratt WB, Lieberman AP, Osawa Y. Targeting Hsp70 facilitated protein quality control for treatment of polyglutamine diseases. Cellular and Molecular Life Sciences : Cmls. (2019) PMID 31552448 DOI: 10.1007/s00018-019-03302-2

  • Morishima Y, Mehta RK, Yoshimura M, Lau M, Southworth DR, Lawrence TS, Pratt WB, Nyati MK, Osawa Y. Chaperone Activity and Dimerization Properties of Hsp90α and Hsp90β in Glucocorticoid Receptor Activation by the Multiprotein Hsp90/Hsp70-Dependent Chaperone Machinery. Molecular Pharmacology. (2018) PMID 29941666 DOI: 10.1124/mol.118.112516

  • Zhang H, Yokom AL, Cheng S, Su M, Hollenberg PF, Southworth DR, Osawa Y. The full-length cytochrome P450 enzyme CYP102A1 dimerizes at its reductase domains and has flexible heme domains for efficient catalysis. The Journal of Biological Chemistry. (2018) PMID 29618513 DOI: 10.1074/jbc.RA117.000600

  • Capper, C. P., Liu, J., McIntosh, L. R., Larios, J. M., Johnson, M. D., Hollenberg, P. F., Osawa, Y., Auchus, R.J., Rae, J. M. (2017). Functional characterization of the G162R and D216H genetic variants of human CYP17A1. Journal of Steroid Biochemistry and Molecular Biology. (2017) DOI: 10.1016/j.jsbmb.2017.12.002

  • Zhang H, Lauver DA, Wang H, Sun D, Hollenberg PF, Chen YE, Osawa Y, Eitzman DT. Significant Improvement Of Antithrombotic Responses To Clopidogrel By Use Of A Novel Conjugate As Revealed In An Arterial Model Of Thrombosis. The Journal of Pharmacology and Experimental Therapeutics. (2016) PMID 27511819 DOI: 10.1124/jpet.116.236034

  • Morishima Y, Zhang H, Lau M, Osawa Y. Improved method for assembly of hemeprotein neuronal NO-synthase heterodimers. Analytical Biochemistry, 511, 24-26. (2016) PMID 27487179 DOI: 10.1016/j.ab.2016.07.031

  • Pratt WB, Gestwicki JE, Osawa Y, Lieberman AP. Targeting Hsp90/Hsp70-based protein quality control for treatment of adult onset neurodegenerative diseases. Annual Review of Pharmacology and Toxicology. 55: 353-71 (2015). PMID 25292434 DOI: 10.1146/annurev-pharmtox-010814-124332

  • Pratt WB, Morishima Y, Gestwicki JE, Lieberman AP, Osawa Y. A model in which heat shock protein 90 targets protein-folding clefts: rationale for a new approach to neuroprotective treatment of protein folding diseases. Experimental Biology and Medicine (Maywood, N.J.). 239: 1405-13 (2014). PMID 24990484 DOI: 10.1177/1535370214539444

  • Yokom AL, Morishima Y, Lau M, Su M, Glukhova A, Osawa Y, Southworth DR. Architecture of the nitric-oxide synthase holoenzyme reveals large conformational changes and a calmodulin-driven release of the FMN domain. The Journal of Biological Chemistry. 289: 16855-65 (2014). PMID 24737326 DOI: 10.1074/jbc.M114.564005

  • Ingelman-Sundberg M, Zhong XB, Hankinson O, Beedanagari S, Yu AM, Peng L, Osawa Y. Potential role of epigenetic mechanisms in the regulation of drug metabolism and transport. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 1725-31 (2013). PMID 23918665 DOI: 10.1124/dmd.113.053157

  • Ahsan A, Ray D, Ramanand SG, Hegde A, Whitehead C, Rehemtulla A, Morishima Y, Pratt WB, Osawa Y, Lawrence TS, Nyati MK. Destabilization of the epidermal growth factor receptor (EGFR) by a peptide that inhibits EGFR binding to heat shock protein 90 and receptor dimerization. The Journal of Biological Chemistry. 288: 26879-86 (2013). PMID 23897823 DOI: 10.1074/jbc.M113.492280

  • Zhang H, Gay SC, Shah M, Foroozesh M, Liu J, Osawa Y, Zhang Q, Stout CD, Halpert JR, Hollenberg PF. Potent mechanism-based inactivation of cytochrome P450 2B4 by 9-ethynylphenanthrene: Implications for allosteric modulation of cytochrome P450 catalysis Biochemistry. 52: 355-364 (2013). PMID 23276288 DOI: 10.1021/bi301567z

  • Wang AM, Miyata Y, Klinedinst S, Peng HM, Chua JP, Komiyama T, Li X, Morishima Y, Merry DE, Pratt WB, Osawa Y, Collins CA, Gestwicki JE, Lieberman AP. Activation of Hsp70 reduces neurotoxicity by promoting polyglutamine protein degradation. Nature Chemical Biology. 9: 112-8 (2013). PMID 23222885 DOI: 10.1038/nchembio.1140

  • Clapp KM, Peng HM, Jenkins GJ, Ford MJ, Morishima Y, Lau M, Osawa Y. Ubiquitination of neuronal nitric-oxide synthase in the calmodulin-binding site triggers proteasomal degradation of the protein. The Journal of Biological Chemistry. 287: 42601-10 (2012). PMID 23109339 DOI: 10.1074/jbc.M112.412494

  • Peng HM, Morishima Y, Pratt WB, Osawa Y. Modulation of heme/substrate binding cleft of neuronal nitric-oxide synthase (nNOS) regulates binding of Hsp90 and Hsp70 proteins and nNOS ubiquitination. The Journal of Biological Chemistry. 287: 1556-65 (2012). PMID 22128174 DOI: 10.1074/jbc.M111.323295

  • Morishima Y, Lau M, Peng HM, Miyata Y, Gestwicki JE, Pratt WB, Osawa Y. Heme-dependent activation of neuronal nitric oxide synthase by cytosol is due to an Hsp70-dependent, thioredoxin-mediated thiol-disulfide interchange in the heme/substrate binding cleft. Biochemistry. 50: 7146-56. (2011) PMID 21755988 DOI: 10.1021/bi200751t

  • Pratt WB. Morishima Y, Peng HM, Osawa Y: Proposal for a Role of the Hsp90/Hsp70-Based Chaperone Machinery in Making Triage Decisions When Proteins Undergo Oxidative and Toxic Damage, Experimental Biology and Medicine, 235:278-289 (2010).

  • Wang AM, Morishima Y, Clapp KM, Peng HM, Pratt WB, Gestwicki JE, Osawa Y, Lieberman AP: Inhibition of Hsp70 by Methylene Blue Affects Signaling Protein Function and Ubiquitination and Modulates Polyglutamine Protein Degradation, J. Biol. Chem. 285:15714-15723 (2010).

  • Clapp KM, Peng HM, Morishima Y, Lau M, Walker VJ, Pratt WB, Osawa Y: C331A Mutant of Neuronal Nitric-Oxide Synthase is Labilized for Hsp70/Chip-Dependent Ubiquitination. J. Biol. Chem. 285: 33642-33651 (2010).